KemPharm, Inc. (NASDAQ:KMPH – Get Rating) – Research analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of KemPharm in a research note issued to investors on Monday, November 14th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will post earnings per share of $0.01 for the year, down from their prior forecast of $0.03. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for KemPharm’s current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for KemPharm’s FY2026 earnings at $1.66 EPS.
A number of other research firms have also recently weighed in on KMPH. Canaccord Genuity Group dropped their price target on KemPharm from $20.00 to $19.00 in a report on Thursday, November 10th. StockNews.com lowered KemPharm from a “hold” rating to a “sell” rating in a research report on Friday, November 11th. Finally, Canaccord Genuity Group assumed coverage on KemPharm in a research report on Thursday, September 15th. They issued a “buy” rating and a $20.00 price objective on the stock.
KemPharm Price Performance
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. UBS Group AG bought a new position in KemPharm in the 2nd quarter valued at $26,000. Invesco Ltd. bought a new position in shares of KemPharm in the 1st quarter worth $51,000. Kingsview Wealth Management LLC bought a new position in shares of KemPharm in the 2nd quarter worth $54,000. Russell Investments Group Ltd. bought a new position in shares of KemPharm in the 1st quarter worth $66,000. Finally, Atom Investors LP bought a new position in shares of KemPharm in the 3rd quarter worth $88,000. 20.85% of the stock is currently owned by institutional investors.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.